| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey, USA; b Breast Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
Correspondence: Francis X. Farrell, Ph.D., Growth Factors Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, 1000 Route 202, Raritan, New Jersey 08869, USA. Telephone: 908-218-6404; Fax: 908-704-4996; e-mail: ffarrell{at}prdus.jnj.com
Erythropoietin (EPO) is the primary regulator of erythropoiesis, stimulating growth, preventing apoptosis, and promoting differentiation of red blood cell progenitors. The EPO receptor belongs to the cytokine receptor superfamily. Although the primary role of EPO is the regulation of red blood cell production, EPO and its receptor have been localized to several nonhematopoietic tissues and cells, including the central nervous system (CNS), endothelial cells, solid tumors, the liver, and the uterus. The presence of EPO receptors and the possibility of EPO signaling in these tissues and cells have led to numerous studies of the effects of EPO at these sites. In particular, expression of EPO and the EPO receptor in cancer cells has generated much interest because of concern that administration of recombinant human erythropoietin (rHuEPO) to patients with breast and other cancer cells expressing the EPO receptor may promote tumor growth via the induction of cell proliferation or angiogenesis. However, evidence supporting a growth-promoting effect has been inconclusive. Moreover, several preclinical studies have shown a beneficial effect of EPO on delaying tumor growth. Further, it is conceivable that increased expression of EPO could reduce tumor hypoxia and ameliorate the deleterious effects of hypoxia on tumor growth, metastasis, and treatment resistance. On the other hand, EPO has also been shown to produce an angiogenic effect in vascular endothelial cells in vitro. However, there is no evidence that these effects occur in vivo to promote tumor growth. EPO and EPO receptors are expressed in neural tissue, and they are upregulated there by hypoxia. Animal studies have shown that administration of epoetin alfa (an rHuEPO) reduces tissue injury due to ischemic stroke, blunt trauma, and experimental autoimmune encephalomyelitis. These findings suggest that epoetin alfa may provide a therapeutic benefit in patients with stroke, trauma, epilepsy, and other CNS-related disorders. Clearly, further study of EPO and the EPO receptor in nonhematopoietic tissue is warranted to determine the potential therapeutic usefulness of rHuEPO as well as to determine the signaling pathway responsible for its effect in vivo.
This article has been cited by other articles:
 |
|
 |
|
  M. BALTAZIAK, M. KODA, A. WINCEWICZ, M. SULKOWSKA, L. KANCZUGA-KODA, and S. SULKOWSKI Relationships of P53 and Bak with EPO and EPOR in Human Colorectal Cancer Anticancer Res, October 1, 2009; 29(10): 4151 - 4156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Hadland and G. D. Longmore Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic Mechanisms J. Clin. Oncol., September 1, 2009; 27(25): 4217 - 4226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Chabowska, M. Sulkowska, A. Chabowski, A. Wincewicz, M. Koda, and S. Sulkowski Erythropoietin and Erythropoietin Receptor in Colorectal Cancer International Journal of Surgical Pathology, July 1, 2008; 16(3): 269 - 276. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Mannello and G. A. M. Tonti Erythropoietin and Its Receptor in Breast Cancer: Putting Together the Pieces of the Puzzle Oncologist, July 1, 2008; 13(7): 761 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Pinto, S. Ribeiro, H. Pontes, S. Thowfeequ, D. Tosh, F. Carvalho, and G. Porto Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBP{alpha} Blood, June 15, 2008; 111(12): 5727 - 5733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fandrey Erythropoietin Receptors on Tumor Cells: What Do They Mean? Oncologist, May 1, 2008; 13(suppl_3): 16 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lundby, Y. Hellsten, M. B. F. Jensen, A. S. Munch, and H. Pilegaard Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle J Appl Physiol, April 1, 2008; 104(4): 1154 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Pelekanou, M. Kampa, M. Kafousi, K. Dambaki, K. Darivianaki, T. Vrekoussis, E. Sanidas, D. D. Tsiftsis, E. N. Stathopoulos, and E. Castanas Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2016 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Keogh, S. P. Yu, and L. Wei The Effect of Recombinant Human Erythropoietin on Neurovasculature Repair after Focal Ischemic Stroke in Neonatal Rats J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 521 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Leo, L.-C. Horn, C. Rauscher, B. Hentschel, A. Liebmann, G. Hildebrandt, and M. Hockel Expression of Erythropoietin and Erythropoietin Receptor in Cervical Cancer and Relationship to Survival, Hypoxia, and Apoptosis Clin. Cancer Res., December 1, 2006; 12(23): 6894 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. LaMontagne, J. Butler, D. J. Marshall, J. Tullai, Z. Gechtman, C. Hall, A. Meshaw, and F. X. Farrell Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol. Cancer Ther., February 1, 2006; 5(2): 347 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Winter, K. A. Shah, L. Campo, H. Turley, R. Leek, R. J. Corbridge, G. J. Cox, and A. L. Harris Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., November 1, 2005; 11(21): 7614 - 7620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Norton Conceptual and Practical Implications of Breast Tissue Geometry: Toward a More Effective, Less Toxic Therapy Oncologist, June 1, 2005; 10(6): 370 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hudis and S. Van Belle Introduction: Examining the Potential Impact of Anemia Treatment on Clinical Outcomes in Anemic Cancer Patients Oncologist, November 1, 2004; 9(suppl_5): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt rHuEPO and Treatment Outcomes: the Clinical Experience Oncologist, November 1, 2004; 9(suppl_5): 55 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig, C. A. Hudis, G. Goss, and B. Leyland-Jones Epoetin Alfa: Future Directions and Future Research Oncologist, November 1, 2004; 9(suppl_5): 70 - 73. [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
